Education
About Us
Working with TipRanks
Follow Us
Virax Biolabs Group Ltd. Class A (VRAX)
NASDAQ:VRAX
VRAX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.74 - $9.00
Previous CloseN/A
Volume267.06K
Average Volume (3M)45.83K
Market Cap
N/A
Enterprise Value$207.17M
Total Cash (Recent Filing)$7.38M
Total Debt (Recent Filing)$603.20K
Price to Earnings (P/E)―
Beta2.30
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.37
Shares Outstanding4,341,956
10 Day Avg. Volume40,308
30 Day Avg. Volume45,833
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.81
Price to Sales (P/S)0.00
P/FCF Ratio-1.70
Enterprise Value/Market CapN/A
Enterprise Value/Revenue651.91
Enterprise Value/Gross Profit6.17K
Enterprise Value/Ebitda-13.81
Forecast
1Y Price Target
$3.00Price Target Upside279.75% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering0
Virax Biolabs Group Ltd. Class A News
PremiumCompany Announcements
Virax Biolabs Announces CFO Resignation and Transition
PremiumCompany Announcements
Virax Biolabs Launches Clinical Study on T Cell Dysfunction
PremiumCompany Announcements
Virax Biolabs Highlights T-Cell Dysfunction in Post-Infection Syndromes
PremiumCompany Announcements
Virax Biolabs to Present at World Immune Regulation Meeting
PremiumCompany Announcements
Virax Biolabs Aligns with US Health Department on Vaccine TransparencyBulls Say, Bears Say
Bulls Say
Collaborative StudyThe company announced that a multi-center longitudinal observational study had started enrolling patients in the UK, conducted in collaboration with the UK’s National Health Service.
Market ExpansionManagement expects to expand ImmuneSelect distribution channels into the U.S markets.
Product LaunchThe research-use-only (RUO) ImmuneSelect portfolio was launched, enabling researchers and drug developers to study T-cell activation, immune profiling, and immune status in infections and conditions linked to chronic inflammation and adaptive immune dysfunction.
Bears Say
Development StageVirax Biolabs is a UK-based development-stage in vitro diagnostics company focused on T cell diagnostics.
Validation StudyThe company is initiating a U.S.-based clinical validation study to support the development of its ViraxImmune platform.
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
0.01%
Mutual Funds
0.31% Other Institutional Investors
99.67% Public Companies and Individual Investors
VRAX FAQ
What was Virax Biolabs Group Ltd. Class A’s price range in the past 12 months?
Virax Biolabs Group Ltd. Class A lowest stock price was $0.74 and its highest was $9.00 in the past 12 months.
What is Virax Biolabs Group Ltd. Class A’s market cap?
Currently, no data Available
When is Virax Biolabs Group Ltd. Class A’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Virax Biolabs Group Ltd. Class A’s earnings last quarter?
Virax Biolabs Group Ltd. Class A released its earnings results on Feb 02, 2023. The company reported -$1.238 earnings per share for the quarter, missing the consensus estimate of N/A by -$1.238.
Is Virax Biolabs Group Ltd. Class A overvalued?
According to Wall Street analysts Virax Biolabs Group Ltd. Class A’s price is currently Undervalued.
Does Virax Biolabs Group Ltd. Class A pay dividends?
Virax Biolabs Group Ltd. Class A does not currently pay dividends.
What is Virax Biolabs Group Ltd. Class A’s EPS estimate?
Virax Biolabs Group Ltd. Class A’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Virax Biolabs Group Ltd. Class A have?
Virax Biolabs Group Ltd. Class A has 4,341,956 shares outstanding.
What happened to Virax Biolabs Group Ltd. Class A’s price movement after its last earnings report?
Virax Biolabs Group Ltd. Class A reported an EPS of -$1.238 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 6.892%.
Which hedge fund is a major shareholder of Virax Biolabs Group Ltd. Class A?
Currently, no hedge funds are holding shares in VRAX
Company Description
Virax Biolabs Group Ltd. Class A
Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits, and med-tech and PPE products for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name; and med-tech and PPE products, such as employee protection equipment products under the ViraxCare brand name, as well as infrared thermometers, pulse oximeters, masks, gloves, and other PPE products. It also distributes nebulizing machines and smart wearable devices that alert employees to help them follow social distance guidelines. In addition, the company operates an online platform that sells ViraxClear and ViraxCare products. It serves clinics, pharmacies, laboratories, hospitals, and other groups, as well as corporations, employees, individual consumers, hospital systems, and public and private institutions. The company operates in Europe, South America, the Asia Pacific, Sub-Saharan Africa, and internationally. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. Virax Biolabs Group Limited was incorporated in 2021 and is headquartered in London, the United Kingdom.
Technical Analysis
Biodexa Pharmaceuticals
―
Salarius Pharmaceuticals
―
Quoin Pharmaceuticals
―
GRI Bio
―
Protagenic Therapeutics
―